Contact
Please use this form to send email to PR contact of this press release:
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
TO:
Please use this form to send email to PR contact of this press release:
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
TO: